Biological Background and Function of GPIHBP1

GPIHBP1 (Glycosylphosphatidylinositol-anchored High-density lipoprotein Binding Protein 1) is a GPI-anchored cell-surface protein expressed predominantly on capillary endothelial cells. It belongs to the Ly6/uPAR superfamily, characterized by a conserved three-fingered LU domain and an N-terminal acidic domain rich in aspartate and glutamate residues.

The primary physiological role of GPIHBP1 is to serve as a molecular shuttle for lipoprotein lipase (LPL). GPIHBP1 binds LPL within the subendothelial space and transcytoses it across the endothelial cell to present it at the luminal surface of capillaries. This process is essential for the intravascular hydrolysis of triglycerides carried in chylomicrons and very-low-density lipoproteins (VLDL), thereby facilitating the delivery of fatty acids to peripheral tissues such as skeletal muscle, heart, and adipose tissue.

Loss-of-function mutations in GPIHBP1 result in the failure of LPL to reach the capillary lumen, leading to severe hypertriglyceridemia and familial chylomicronemia syndrome (FCS). These observations underscore the non-redundant and essential nature of GPIHBP1 in plasma lipid metabolism.

Biochemical Properties of Recombinant Human GPIHBP1 Protein

Recombinant Human GPIHBP1 Protein is typically produced as a soluble, secreted form of the native GPI-anchored protein. In recombinant expression systems, the GPI-anchor signal is commonly replaced with a secretion-compatible C-terminus or an affinity tag (such as His or Fc) to facilitate purification and functional assays in solution-based formats.

The protein encompasses the key structural elements responsible for LPL binding: the acidic N-terminal domain, which mediates electrostatic interactions with LPL's heparin-binding sites, and the LU domain, which provides high-affinity protein–protein interaction surfaces. Post-translational modifications, including glycosylation, may influence binding kinetics and protein stability depending on the expression host system used.

Researchers should confirm the specific tag, expression host, purity grade, and formulation buffer when selecting recombinant GPIHBP1 for downstream assays. These parameters directly affect compatibility with binding studies, structural analyses, and cell-based assays.

Research Applications

Recombinant Human GPIHBP1 Protein supports a broad range of in vitro and biochemical research applications:

• LPL–GPIHBP1 Interaction Studies: GPIHBP1 is widely used in binding assays (ELISA, SPR, co-immunoprecipitation) to characterize the interaction interface between LPL and GPIHBP1, including the effects of disease-associated mutations on binding affinity.
• Structural Biology: Recombinant GPIHBP1 has been used in X-ray crystallography and cryo-EM studies to resolve the three-dimensional structure of the LPL–GPIHBP1 complex, providing mechanistic insights into LPL stabilization and activation.
• Antibody Development and Screening: The recombinant protein serves as an antigen for generating and validating anti-GPIHBP1 antibodies, including research-grade and potential therapeutic autoantibody models.
• Disease Mechanism Research: Functional assays using recombinant GPIHBP1 help elucidate the pathophysiology of hypertriglyceridemia, FCS, and acquired GPIHBP1 autoantibody syndrome.
• Drug Discovery: GPIHBP1 is an emerging target for modulating LPL activity in metabolic disease; recombinant protein supports screening of small molecules or biologics that modulate GPIHBP1–LPL interactions.

Handling, Storage, and Quality Considerations

To maintain the activity and integrity of Recombinant Human GPIHBP1 Protein, researchers should adhere to the following general guidelines:

• Storage: Store lyophilized protein at –20 °C or –80 °C as specified in the product datasheet. Reconstituted protein should be aliquoted to avoid repeated freeze–thaw cycles, which can lead to protein aggregation and loss of activity.
• Reconstitution: Reconstitute in the recommended buffer (typically sterile PBS or the manufacturer-specified diluent). Allow the lyophilized cake to dissolve gently; avoid vigorous vortexing.
• Purity and Endotoxin: Confirm purity (typically ≥90% by SDS-PAGE) and endotoxin levels before use in cell-based or in vivo assays to prevent non-specific inflammatory responses.
• Carrier Proteins: For long-term storage of low-concentration preparations, consider addition of a carrier protein (e.g., 0.1% BSA) as specified by the manufacturer.

Always consult the specific product datasheet provided with the lot for validated storage conditions, activity data, and recommended assay formats.